S59 - Migraine: Impact, Treatment Patterns and Resource Utilization
| Event Time: | Friday May 10, 2019 1:00 pm to 3:00 pm |
| Topic(s): | Headache |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Short-term Outcomes in Patients with Migraine and Substance Abuse: A 5-year Review Utilizing the Nationwide Readmission Database 2010-14 |
Disclosure: Dr. Brock has nothing to disclose.
|
| 1:00 PM | 002 | Life With Migraine, Effect on Relationships, Career and Finances, and Overall Health and Well-Being: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study |
Disclosure: Dr. Buse has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Dawn Buse PhD has received honoraria from Allergan Amgen Biohaven Lilly Teva and Promius. Dr. Buse has received personal compensation in an editorial capacity for editorial board of Current Pain and Headache Reports. Dr. Buse has received research support from Amgen.
|
| 1:00 PM | 003 | Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a US Commercially Insured Population |
Disclosure: Dr. Marcus has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan.
|
| 1:00 PM | 004 | Women with migraine vary in time to peak headache pain intensity, functional impairment and pain interference based on menstrual migraine status: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study |
Disclosure: Dr. Pavlovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Alder, and Biohaven Pharma.
|
| 1:00 PM | 005 | Familial Transmission of Migraine and Mood Disorders- Evidence from a High Risk Study |
Disclosure: Dr. Lateef has nothing to disclose.
|
| 1:00 PM | 006 | Demographics, Headache Characteristics, and Other Factors Associated With Opioid Use in People With Migraine: Results From the CaMEO Study |
Disclosure: Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven, which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation, the National Headache Foundation, and Amgen.
|
| 1:00 PM | 007 | Opioid Use, Rebound Headache, and Resource Utilization Among Migraine Patients With Insufficient Response to Triptans Based on Real-World Data |
Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stephen D. Silberstein, MD, is a consultant and/or advisory panel member for and has received honoraria from Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva.. Dr. Silberstein has received research support from His employer receives research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare..
|
| 1:00 PM | 008 | Patterns and Characterization of Acute Prescription Migraine Medication Use: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study |
Disclosure: Dr. Hutchinson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Biohaven, ElectroCore, Eli Lilly, Supernus, and Teva.
|
| 1:00 PM | 009 | Predictors of 30-Day Readmission and Prolonged Length of Stay After Hospitalization for Status Migrainosus: A Review of 5-Year National Data |
Disclosure: Dr. Ghattas has nothing to disclose.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 9:30 AM-11:30 AM |
|---|
|
C14 -
Child Neurology: Headache
Amy Gelfand MD |
| 7:00 AM-9:00 AM |
|---|
|
C46 -
Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder)
Dario Beltran MD, FAAN, Jose Merino MD, MPhil, FAAN |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C53 -
Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine
Deborah Friedman MD, MPH, FAAN |
| 3:30 PM-5:30 PM |
|
C70 -
Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches
Christopher Boes MD, FAAN |
| 9:15 AM-12:00 PM |
|---|
|
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C91 -
Neurology Update III: Headache, Neuro-otology, and Epilepsy
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
S17 -
Headache: Clinical Trials I
|
| 3:30 PM-5:30 PM |
|
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
|
S20 -
Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine
|
| 9:15 AM-11:30 AM |
|---|
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
C138 -
Hot Topics in Headaches and Related Disorders I: Unusual Headaches, Childhood Headaches, and Concussion Management
Amy Gelfand MD |
| 3:30 PM-5:30 PM |
|
C156 -
Hot Topics in Headaches and Related Disorders II: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances
Andrew Charles MD |
| 7:00 AM-9:00 AM |
|---|
|
C173 -
Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders
(Registration Required)
Amaal Starling MD, Rashmi Halker Singh MD, FAAN |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 11:45 AM-12:30 PM |
|
Eating Your Way to Fewer Migraines
Belinda Savage-Edwards MD, FAAN, Chef Tess Connor |
| 1:00 PM-1:45 PM |
|
Headache Neuromodulation Therapy
Heidi Schwarz MD, FAAN |
| 1:00 PM-3:00 PM |
|
C187 -
Comprehensive Migraine Update I: Migraine Diagnosis, Pathophysiology, and Comorbidities
Gretchen Tietjen MD |
|
S38 -
Headache: Clinical Trials II
|
| 3:30 PM-5:30 PM |
|
C203 -
Comprehensive Migraine Update II: Pharmacologic and Non-Pharmacologic Therapies
Gretchen Tietjen MD |
| 7:00 AM-9:00 AM |
|---|
|
C210 -
Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management
Kathleen Digre MD, FAAN |
| 11:30 AM-6:30 PM |
|
P5 -
Poster Session 5
|
| 1:00 PM-3:00 PM |
|
C219 -
Therapy in Neurology III: Epilepsy and Headache
David Dodick MD, FAAN |
| 7:00 PM-10:00 PM |
|
C241 -
Case Studies: Challenging Headache Cases
Kathleen Digre MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
| 11:45 AM-12:45 PM |
|
Friday Grand Finale: Neuroimaging
|
| 1:00 PM-3:00 PM |